Actively Recruiting
dEtection of rheumAtoid aRthritis - Interstitial Lung dIseasE by Thoracic ultRasound
Led by University Hospital, Tours · Updated on 2026-04-30
280
Participants Needed
1
Research Sites
119 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Rheumatoid arthritis is an autoimmune disease that can affect various organs, including the lungs, and lead to rheumatoid arthritis-interstitial lung disease (RA-ILD). RA-ILD is responsible for increased mortality in rheumatoid arthristis (RA) patients. The prevalence of RA-ILD varies according to the screening tool used. The current gold standard is chest CT, but this is an expensive, time-consuming and irradiating examination, and recommendations on when and how often it should be performed are not clearly established. Lung ultrasound (LUS) is an emerging tool for the detection of lung parenchymal damage, particularly in systemic scleroderma and idiopathic pulmonary fibrosis (IPF). LUS is a non-irradiating, non-expensive examination that can be performed rapidly. The aim of our study is to evaluate LUS as a screening tool for RA-ILD, in patients with risk factors for developing RA-ILD.
CONDITIONS
Official Title
dEtection of rheumAtoid aRthritis - Interstitial Lung dIseasE by Thoracic ultRasound
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patient (age > 18 years) followed at CHU of Tours
- Diagnosis of rheumatoid arthritis validated according to ACR 2010 criteria, EULAR classification, regardless of time since diagnosis
- Patient who has had or will have a thoracic CT scan and pulmonary function tests performed as part of routine care in the 6 months preceding or following inclusion
- Patient with at least two risk factors for developing RA-ILD among: male sex, active or former smoker with at least 20 pack-years, age > 60 years, elevated rheumatoid factor and/or anti-CCP antibodies at diagnosis or during disease, high RA activity score (DAS28 > 3.2)
You will not qualify if you...
- Diagnosis of congenital lung disease
- Diagnosis of another autoimmune disease associated with RA linked to ILD development (systemic sclerosis, myositis, dermatomyositis, mixed connective tissue disease, systemic lupus erythematosus, or ANCA vasculitis except secondary Gougerot-Sjögren's syndrome)
- Current or treated lung cancer
- Thoracic irradiation
- Thoracic transplant
- Previous invasive thoracic procedures
- Diseases causing pleural thickening (silicosis, asbestosis, known pleural plaques, pleural sequelae of tuberculosis)
- Pregnant or breastfeeding women
- Patient under legal protection (guardianship, curatorship, or safeguard of justice)
- Patient who has objected to data processing
- Current or recent (within one month) lung infection prior to lung ultrasound
- Presence of liquid or gaseous pleural effusion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
university hospital Tours
Tours, France, 37000
Actively Recruiting
Research Team
S
Sylvie LEGUE
CONTACT
A
Ariane MERLIN-DOMONT
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here